Navigation Links
Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
Date:4/22/2013

KING OF PRUSSIA, Pa., April 22, 2013 /PRNewswire/ -- Trevena, Inc. a clinical stage pharmaceutical company today announced that its President and CEO, Dr. Maxine Gowen will present at the 12th Annual Needham Healthcare Conference on May 1, 2013, 10:00am, at Grand Hyatt New York.  

Dr. Gowen will provide a detailed overview of the company's most advanced clinical programs which include TRV027, a biased ligand for the treatment of acute heart failure, which is currently in Phase 2 studies, and TRV130, in Phase 1b studies for acute pain where intravenous therapy is needed. First-in-man study results on the safety, tolerability, and pharmacology of TRV130 in healthy volunteers were recently presented at the American Academy of Neurology.

The complete slide presentation of Dr Gowen's presentation will be available on Trevena's website (www.trevenainc.com) under the About Trevena tab.

Dr. Gowen will be available for one-on-one meetings with the investment community during the conference. Please contact conference organizers to secure a meeting time.

About Trevena and Biased Ligands

Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR, to unlock new biology and avoid drug adverse effects.  The discovery platform is applicable to a wide range of druggable targets and diseases.  Trevena is based in King of Prussia, Pennsylvania and is backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company.

CONTACT: Kimberly Minarovich , 917-533-3268, kminarovich@christensenir.com


'/>"/>
SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmagen to Present Strategic Vision for Solving Nations Parenteral Drug Shortage Crisis at 2013 BIO International Convention
2. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
3. Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
4. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
5. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Cantel Medical To Present At Needham 12th Annual Healthcare Conference
8. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
9. Soligenix to Present at World Vaccine Congress & Expo
10. 20+ SynCardia Certified Centers to Present Record Number of Total Artificial Heart Abstracts at ISHLT
11. Novocure Presents Preclinical Data at the American Association for Cancer Research (AACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)...   , ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung ... plus guter , Reinigung des ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... von der MORA-Studie der Phase III für NER1006 ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 2016 , ... New studies published today by the ... states. The outcomes examined in these studies include recovery of physical health and ... medical care. , “The goal of the studies is to provide information about ...
(Date:5/25/2016)... ... 25, 2016 , ... The World Molecular Imaging Society (WMIS) ... The focus of ADDMI-IG will be geared towards how using molecular imaging can ... ADDMI-IG WMIS will provide a platform for productive discussions about the implementation of ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... solutions to industries ranging from medical and pharmaceutical, to food and HVAC facilities. ... well as on-site training. , For medical applications, Afrimesure offers a variety ...
(Date:5/25/2016)... ... 25, 2016 , ... The University of San Francisco (USF) has named Margaret ... a team of more than 100 full-time faculty and staff, and serve as a ... late August. , Baker comes to USF from the University of Washington in Seattle, ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to cycle ... Christina Austin - CEO of Pixel Film Studios. , With the FCPX LUT ... stylish color grades to their footage. A LUT is a Lookup Table that contains ...
Breaking Medicine News(10 mins):